EU
Emory University Portfolio holdings
AUM
$27.7M
This Quarter Return
+3.18%
1 Year Return
+31.53%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$102M
AUM Growth
–
Cap. Flow
+$102M
Cap. Flow
% of AUM
100%
Top 10 Holdings %
Top 10 Hldgs %
47.6%
Holding
42
New
42
Increased
–
Reduced
–
Closed
–
Top Buys
| 1 |
Berkshire Hathaway Class A
BRK.A
|
$28.6M |
| 2 |
Aclaris Therapeutics
ACRS
|
$2.46M |
| 3 |
Neurogene
NGNE
|
$2.37M |
| 4 |
SMC
Summit Midstream Corporation
SMC
|
$2.2M |
| 5 |
Acadia Pharmaceuticals
ACAD
|
$2.2M |
Top Sells
No sells this quarter
Sector Composition
| 1 | Healthcare | 37.19% |
| 2 | Financials | 36.35% |
| 3 | Energy | 6.89% |
| 4 | Technology | 6.32% |
| 5 | Consumer Discretionary | 4.89% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Berkshire Hathaway Class A
BRK.A
$1.09T
| $28.6M | 28.12% | +117 | New | +$28.6M |
|
|
2
Aclaris Therapeutics
ACRS
$209M
| $2.46M | 2.42% | +90,704 | New | +$2.46M |
|
|
3
Neurogene
NGNE
$264M
| $2.37M | 2.34% | +143,691 | New | +$2.37M |
|
|
SMC
4
Summit Midstream Corporation
SMC
$282M
| $2.2M | 2.17% | +87,560 | New | +$2.2M |
|
|
5
Acadia Pharmaceuticals
ACAD
$4.38B
| $2.2M | 2.16% | +76,121 | New | +$2.2M |
|
|
ZGNX
6
DELISTED
Zogenix, Inc.
ZGNX
| $2.16M | 2.13% | +177,841 | New | +$2.16M |
|
|
ALXN
7
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $2.16M | 2.13% | +17,657 | New | +$2.16M |
|
8
Ascendis Pharma
ASND
$11.8B
| $2.12M | 2.09% | +104,793 | New | +$2.12M |
|
9
Incyte
INCY
$16.5B
| $2.07M | 2.03% | +20,601 | New | +$2.07M |
|
|
DBVT
10
DBV Technologies
DBVT
$264M
| $2.05M | 2.02% | +58,256 | New | +$2.05M |
|
11
Ardelyx
ARDX
$1.53B
| $1.98M | 1.95% | +139,357 | New | +$1.98M |
|
|
SIOX
12
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
| $1.97M | 1.94% | +158,834 | New | +$1.97M |
|
13
BioMarin Pharmaceuticals
BMRN
$11.2B
| $1.91M | 1.88% | +23,047 | New | +$1.91M |
|
|
GHDX
14
DELISTED
Genomic Health, Inc.
GHDX
| $1.89M | 1.86% | +64,147 | New | +$1.89M |
|
|
ACHN
15
DELISTED
Achillion Pharmaceuticals, Inc.
ACHN
| $1.88M | 1.85% | +454,102 | New | +$1.88M |
|
16
Nektar Therapeutics
NKTR
$568M
| $1.87M | 1.84% | +152,563 | New | +$1.87M |
|
17
CBRE Group
CBRE
$48.2B
| $1.79M | 1.76% | +56,765 | New | +$1.79M |
|
18
Allison Transmission
ALSN
$7.3B
| $1.77M | 1.74% | +52,527 | New | +$1.77M |
|
19
Bread Financial
BFH
$3.09B
| $1.77M | 1.74% | +7,734 | New | +$1.77M |
|
20
TG Therapeutics
TGTX
$4.65B
| $1.77M | 1.74% | +379,499 | New | +$1.77M |
|
21
Microsoft
MSFT
$3.77T
| $1.75M | 1.72% | +28,152 | New | +$1.75M |
|
22
Morgan Stanley
MS
$240B
| $1.74M | 1.71% | +41,070 | New | +$1.74M |
|
|
BHI
23
DELISTED
Baker Hughes
BHI
| $1.73M | 1.7% | +26,634 | New | +$1.73M |
|
24
Arch Capital
ACGL
$34.2B
| $1.73M | 1.7% | +20,039 | New | +$1.73M |
|
25
CommScope
COMM
$3.55B
| $1.73M | 1.7% | +46,474 | New | +$1.73M |
|